International Isotopes Inc. Reveals Financial Performance for Q3 2025

International Isotopes Inc. Financial Results for Q3 2025

International Isotopes Inc. (OTCQB: INIS) has disclosed its financial performance for the third quarter and the first nine months of fiscal year 2025, unveiling a mixed bag of results that point to challenges and areas of growth. The report showcases the company’s ongoing resilience despite facing significant setbacks in raw material supplies.

Overview of Financial Performance

For the third quarter ending September 30, 2025, International Isotopes reported revenues of $3,277,816, a decline of 16% or $646,628 compared to the same quarter in the previous year. However, revenue for the nine-month period rose slightly to $10,172,036, reflecting a modest increase of 2% or $173,901 from the prior year.

The company also recorded a net loss of $203,601 in the third quarter of 2025, a notable shift from a net profit of $150,251 in Q3 of 2024. The cumulative net loss for the first nine months of 2025 ballooned to $477,080, worsening by $237,245 compared to the same timeframe last year. Non-GAAP EBITDA tumbled to $14,985 from $210,590, highlighting the company's struggle to maintain profitability amidst falling product lines.

Reasons for Revenue Discrepancies

These financial variations were primarily driven by interruptions in the supply of critical raw materials for Theranostics Products in March, July, and August, as well as shortages in Gd-153 for Calibration Reference Products. The company estimates these outages resulted in revenue losses exceeding $400,000 for Q3 and over $750,000 across the first nine months.

Shahe Bagerdjian, the President and CEO of INIS, pointed out the challenges the company faced regarding raw material shortages. He noted substantial outages in July and August prior to securing a new FDA-approved supplier, which commenced operations in September 2025. Furthermore, the ongoing shortage of Gadolinium-153, which the company sources from an exclusive foreign government supplier, has hindered the Calibration Reference Products segment. Nevertheless, INIS has experienced a surge in customers for its Theranostics products and ongoing growth in its Calibration Reference division.

Segment Analysis

1. Theranostics Products: The segment saw revenues decrease by 17% to $5,176,740 this year compared to $6,257,410 in 2024. The drop reflects the impact of critical raw material outages despite recovering some previously lost customers.

2. Calibration Reference Products (formerly Nuclear Medicine Standards): Revenues soared by 57% to $3,301,673 attributed to the remedy for the global shortage of Cobalt-57 isotopes and new product launches. The name change was aimed at better representing the range of products manufactured.

3. Cobalt Products: Sales dipped by 8%, totaling $1,517,147 due to seasonal sales fluctuations.

4. Medical Devices: This newly established segment generated $176,476, indicating growth as the company moves toward commercializing several products.

5. Fluorine Products: Reported no sales, incurring expenses related to the maintenance of its planned de-conversion facility.

Continuous Improvement Strategies

Despite the setbacks, International Isotopes has invested substantially in internal improvements. The company successfully reduced selling, general, and administrative (SGA) costs by 24% in Q3 and 11% year-to-date, while further enhancements to corporate governance have been integrated, including a new Nominating Corporate Governance Committee and the addition of Dr. Duke Fu to the board.

The company is optimistic about stabilizing its revenue stream as raw material supplies normalize and plans to launch new products under its RadQual and PhanQual brands.

Future Outlook

International Isotopes Inc. remains committed to improving operational efficiency while navigating significant global challenges. The management remains cautiously optimistic about future growth prospects as they enhance their product lines and seek to mitigate raw material supply risks effectively. Investors are encouraged to keep an eye on upcoming developments as the firm strives to turn around its financial performance in the quarters to come.

For a complete version of the earnings release, visit the Investor Center on the INIS website.